Osimertinib-Induced Cardiomyopathy

[1]  J. Ensor,et al.  Osimertinib-Induced Cardiotoxicity , 2019, JACC. CardioOncology.

[2]  J. Ensor,et al.  Osimertinib induced cardio-toxicity: A retrospective review of FDA adverse events reporting system (FAERS). , 2019, Journal of Clinical Oncology.

[3]  S. Novello,et al.  Osimertinib-induced Cardiac Dysfunction in EGFR-Mutated Lung Cancer: A Case Series of Five Patients , 2018 .

[4]  L. Scott.  Osimertinib as first-line therapy in advanced NSCLC: a profile of its use , 2018, Drugs & therapy perspectives : for rational drug selection and use.

[5]  A. Oto,et al.  Development of Heart Failure After Initiation of Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-Mutant Adenocarcinoma of the Lung , 2018 .

[6]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[7]  T. Naito,et al.  Cardiac Dysfunction Caused by Osimertinib. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  K. Kiura,et al.  Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC) , 2017, Internal medicine.

[9]  T. Mitsudomi,et al.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[10]  W. J. Wu,et al.  Trastuzumab cardiotoxicity: from clinical trials to experimental studies , 2016, British journal of pharmacology.

[11]  Sherry-Ann Brown,et al.  Systems biology approaches to adverse drug effects: the example of cardio-oncology , 2015, Nature Reviews Clinical Oncology.

[12]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[13]  G. D. De Keulenaer,et al.  Molecular Mechanisms of Cardiotoxicity Induced by ErbB Receptor Inhibitor Cancer Therapeutics , 2012, International journal of molecular sciences.

[14]  N. Hynes,et al.  ErbB receptors: directing key signaling networks throughout life. , 2004, Annual review of pharmacology and toxicology.

[15]  A. Park,et al.  CENTER FOR DRUG EVALUATION AND RESEARCH , 2009 .